[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"essential-thrombocythemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:essential-thrombocythemia":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,19,0,[8,45,57,82,106,132,161,192,216,244,268,290,315,348,371,395,419,454,474],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100054110","phase-3-bomedemstat-vs-hydroxyurea-for-essential-thrombocythemia-mk-3543-007-100054110",false,"NCT06456346","Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)","A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study to Evaluate the Efficacy and Safety of Bomedemstat (MK-3543) Versus Hydroxyurea in Cytoreductive Therapy Naïve Essential Thrombocythemia Participants","Inclusion Criteria:\n\n* Diagnosis of Essential Thrombocythemia (ET) based on World Health Organization Criteria for myeloproliferative neoplasms, and an indication for cytoreductive therapy regardless of age or risk status\n* Has a centrally assessed bone marrow fibrosis score of Grade 0 or Grade 1, as per a modified version of the European Consensus Criteria for Grading Myelofibrosis\n* Has received no prior cytoreductive treatment for their ET\n* Human Immunodeficiency Virus (HIV)-infected participants have well controlled HIV on antiretroviral therapy\n* Participants who are Hepatitis B surface antigen (HBsAg) positive are eligible if they have received Hepatitis B Virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load\n* Participants with history of Hepatitis C Virus (HCV) infection are eligible if HCV viral load is undetectable\n\nExclusion Criteria:\n\n* History of any illness\u002Fimpairment of gastrointestinal function that might interfere with drug absorption\n* History of a malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years\n* HIV-infected participants with a history of Kaposi's sarcoma and\u002For Multicentric Castleman's Disease\n* Has an active infection requiring systemic therapy\n* Has had a major surgery \\\u003C4 weeks prior to first dose of study intervention or has not recovered from side effects of major surgery \\>4 weeks prior to first dose","ALL","18 Years",{"count":19,"type":20},300,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","The purpose of this study is to evaluate the efficacy and safety of bomedemstat compared with hydroxyurea in cytoreductive therapy naïve essential thrombocythemia (ET) participants for whom cytoreductive therapy is indicated. Its primary objective is to compare bomedemstat to hydroxyurea with respect to durable clinicohematologic response (DCHR). The primary hypothesis is that bomedemstat is superior to hydroxyurea with respect to DCHR.",[26],"Essential Thrombocythemia",[28,29,30,31],"essential thrombocythemia","ET","bomedemstat","IMG-7289","RECRUITING","2026-07-10",{"date":35,"type":36},"2026-07-13","ACTUAL",{"date":38,"type":36},"2024-07-16",{"date":40,"type":20},"2028-03-24",{"name":42,"class":43},"Merck Sharp & Dohme LLC","INDUSTRY",171,{"id":46,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":21,"phases":48,"briefSummary":24,"conditions":49,"keywords":50,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":54,"completionDateStruct":55,"leadSponsor":56,"locationsCount":44},"100551150",{"count":19,"type":20},[23],[26],[28,29,30,31],"2026-06-24",{"date":53,"type":36},"2026-06-26",{"date":38,"type":36},{"date":40,"type":20},{"name":42,"class":43},{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":65,"targetDuration":4,"studyType":67,"phases":4,"briefSummary":68,"conditions":69,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":81},"100642891","creta-clopidogrel-responsiveness-in-essential-thrombocithemia-100642891","NCT07645755","CRETA (Clopidogrel Responsiveness in Essential ThrombocithemiA)","Evaluation of Response to Clopidogrel in Patients With Essential Thrombocythemia","CRETA","Inclusion Criteria:\n\n1. Male or female subjects age ≥ 18 years;\n2. Confirmed diagnosis of ET according to the 2022 WHO classification criteria30;\n3. Patients treated with clopidogrel 75 mg od as antithrombotic prophylaxis since at least 3 weeks, as per the indication of the referring hematologist;\n4. Ability to understand the nature of the study and voluntarily provide written informed consent patients whose responsiveness to the standard clopidogrel regimen was determined, based on clinical practice, using the VN-P2Y12 method.\n\nExclusion Criteria:\n\n1. Platelet count \\>1,000,000\u002FμL on three separate determinations within the 2 months prior to enrollment;\n2. Need for anticoagulant therapy;\n3. Concomitant use of other antiplatelet agents;\n4. Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs) (i.e \\> 3 days per week);\n5. Chronic corticosteroid therapy exceeding a daily dose equivalent to prednisone 5 mg",{"count":66,"type":20},50,"OBSERVATIONAL","Essential thrombocythemia (ET) is a chronic myeloproliferative neoplasm associated with increased platelet production and activation, leading to a high risk of thrombotic complications. Low-dose aspirin is the standard antiplatelet therapy for thrombosis prevention; however, the accelerated platelet turnover characteristic of ET results in rapid recovery of platelet function, making once-daily aspirin insufficient in many patients. Consequently, twice-daily low-dose aspirin is currently recommended to achieve adequate and sustained platelet inhibition.\n\nFor patients intolerant to aspirin, clopidogrel 75 mg\u002Fday is the approved alternative. Clopidogrel irreversibly inhibits the platelet P2Y12 receptor, but its pharmacodynamic effect is highly variable because it is a prodrug requiring metabolic activation. Studies in non-ET populations have shown that higher clopidogrel doses (150 mg\u002Fday) provide stronger and more consistent platelet inhibition without significantly increasing bleeding risk.\n\nEvidence on clopidogrel use in ET is limited, but available data suggest that standard-dose therapy may result in inadequate platelet inhibition, potentially reducing antithrombotic efficacy. Platelet function testing can identify patients with high residual platelet reactivity (\"poor responders\"), who may benefit from dose escalation. Therefore, in ET patients requiring clopidogrel therapy, assessment of platelet responsiveness may help optimize treatment, ensuring adequate platelet inhibition and potentially improving protection against thrombotic events.",[26],"NOT_YET_RECRUITING","2026-06-09",{"date":73,"type":36},"2026-06-12",{"date":75,"type":20},"2026-07-15",{"date":77,"type":20},"2027-12-31",{"name":79,"class":80},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","OTHER",2,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":21,"phases":92,"briefSummary":93,"conditions":94,"keywords":95,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":4},"100643299","phase-3-a-phase-3-study-of-inca033989-versus-best-available-therapy-in-participants-with-essential-thrombocythemia-100643299","NCT07623200","A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia","A Phase 3, Randomized, Open-Label Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia and a CALR Mutation Previously Treated With Cytoreductive Therapy (EXCALIBUR-ET2)","EXCALIBUR-ET2","Inclusion Criteria:\n\n* Confirmed diagnosis of high-risk ET.\n* Presence of mutCALR.\n* Prior treatment with at least 1 cytoreductive therapy.\n\nExclusion Criteria:\n\n* Presence of any hematologic malignancy other than ET.\n* Major bleeding or thrombosis within the last 3 months prior to study enrollment.\n* Any prior allogenic or autologous stem-cell transplantation.\n* Unresolved toxicity ≥ Grade 2 from previous therapy except for stable chronic toxicities (Grade 2) not expected to resolve, such as stable Grade 2 peripheral neuropathy.\n* Prior nonhematologic malignancy except for the following: Malignancy treated with curative intent and with no evidence of active disease for more than 2 years before screening. Adequately treated carcinoma in situ without current evidence of disease.\n\nOther protocol-defined Inclusion\u002FExclusion Criteria apply.",{"count":91,"type":20},426,[23],"This study is being conducted to evaluate INCA033989 versus best available therapy in participants with essential thrombocythemia and a CALR mutation previously treated with cytoreductive therapy.",[26],[96,97],"calreticulin (CALR)","mutCALR","2026-06-05",{"date":71,"type":36},{"date":101,"type":20},"2026-07-31",{"date":103,"type":20},"2030-11-01",{"name":105,"class":43},"Incyte Corporation",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":21,"phases":115,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":81},"100520970","phase-2-curcumin-to-improve-inflammation-and-symptoms-in-patients-with-clonal-cytopenia-of-undetermined-significance-low-risk-myelodysplastic-syndrome-and-myeloproliferative-neoplasms-100520970","NCT06063486","Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms","A Phase 2, Double-blind, Randomized Study to Compare the Effect of Curcumin Versus Placebo on Inflammatory Cytokines, Symptoms and Disease Parameters in Clonal Cytopenia of Undetermined Significance (CCUS), Low-Risk Myelodysplastic Syndrome (LR-MDS), and Myeloproliferative Neoplasms (MPNs)","Inclusion Criteria:\n\n* Age \\>= 18\n* Eastern Cooperative Oncology Group (ECOG) =\\\u003C 2\n* Ability to understand and willingness to sign a written informed consent\n* Diagnosis of polycythemia vera (PV), essential thrombocytosis (ET) or myelofibrosis (MF) per World Health Organization (WHO) 2016 diagnostic criteria\n\n  * Presence of at least one symptom measurable using the MPN-\u002FSymptom Assessment Form (SAF) with a severity greater than 3\n  * MPN patients determined to have stable disease undergoing surveillance and unlikely to require initiation of new cytoreductive therapy (i.e., hydroxyurea, ruxotinib, interferon within the study period); patients on a stable dose of hydroxyurea for at least 6 months who meet the other inclusion\u002Fexclusion criteria may be included\n* A diagnosis of CCUS or LR-MDS\n\n  * CCUS defined as persistent cytopenia for \\> 6 months (hemoglobin \\[Hgb\\] \\\u003C 11.3 g\u002FdL \\[7 mmol\u002FL\\] in women and Hgb \\\u003C 12.9 g\u002FdL \\[8 mmol\u002FL\\] in men, platelet \\\u003C 150 x 10\\^9\u002FL or neutrophils \\\u003C 1.8 x 10\\^9\u002FL), normal cytogenetics, presence of detectable MDS associated mutations and bone marrow morphology non-diagnostic of MDS or any other malignancies\n  * LR-MDS as defined by WHO 2016 diagnosis criteria\n  * Minimum baseline symptom score of 25 in the fatigue section of the symptom questionnaire\n\nExclusion Criteria:\n\n* Patients with intake of curcumin as a dietary supplement, including multivitamin and unwillingness to quit more than 24 hours before study start\n* Patients with inability to understand and adhere to information given\n* Patients receiving active treatment for another malignancy except with hormonal therapy for a malignancy considered to be in remission or growth factors (erythropoietin, granulocyte colony-stimulating factor \\[G-CSF\\] and luspatercept)\n* Patients with intermediate or high-risk MDS\n* Patients must not be pregnant or nursing\n* Patients must not be on any oral or intravenous steroid or any other anti-inflammatories (ibuprofen \\> 200mg\u002Fweek or 400mg\u002Fmonth, naproxen of any dose, \\> 325mg aspirin daily, any herbal anti-inflammatory concoction of any dose)",{"count":114,"type":20},30,[116],"PHASE2","This phase II trial evaluates how a curcumin supplement (C3 complex\u002FBioperine) changes the inflammatory response and symptomatology in patients with clonal cytopenia of undetermined significance (CCUS), low risk myelodysplastic syndrome (LR-MDS), and myeloproliferative neoplasms (MPN). Chronic inflammation drives disease development and contributes to symptoms experienced by patients with CCUS, LR-MDS, and MPN. Curcumin has been shown to have anti-inflammatory and anti-cancer properties and has been studied in various chronic illnesses and hematologic diseases.",[119,26,120,121,122],"Clonal Cytopenia of Undetermined Significance","Myelodysplastic Syndrome","Myelofibrosis","Polycythemia Vera","2026-03-24",{"date":125,"type":36},"2026-03-27",{"date":127,"type":36},"2024-03-01",{"date":129,"type":20},"2027-03-01",{"name":131,"class":80},"University of Southern California",{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":21,"phases":141,"briefSummary":142,"conditions":143,"keywords":147,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":160},"100454547","phase-3-avajak-apixabanrivaroxaban-versus-aspirin-for-primary-prevention-of-thrombo-embolic-complications-in-jak2v617f-positive-myeloproliferative-neoplasms-100454547","NCT05198960","AVAJAK: Apixaban\u002FRivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms","AVAJAK","Inclusion Criteria:\n\n* Patients with diagnosis of PV or ET or PreMF according to WHO or BSCH criteria (bone marrow biopsy not compulsory).\n* Patients with JAK2V617F mutation (threshold allele burden \\> 1%).\n* Patients considered as \"high-risk\" patients:\n\n  1. based on age (\\> 60-year-old)\n  2. based on thrombotic history (compatible with antithrombotic randomization) but aged ≥ 18-year-old.\n* Length of time from MPN diagnostic to inclusion will not exceed 12 months.\n\nExclusion Criteria:\n\n* Contra-indication to aspirin or DOAC due to allergic situation or recent history of major bleeding.\n* Formal indication of treatment with aspirin or DOAC (thus precluding randomization).\n* Inability to give informed consent.\n* Patients under curatorship\u002Fguardianship\n* Concomitant use of a strong inhibitor or inducer of CYP3A4 (like ruxolitinib).\n* Chronic liver disease or chronic hepatitis.\n* Renal insufficiency with creatinine \\\u003C30 ml\u002Fmn on Cockcroft and Gault Formula\n* Patient considered at high-risk of bleeding: patients with current or recent major or clinical relevant non major bleeding gastrointestinal or cerebral bleedings\n* Planned pregnancy within 24 months\n* No appropriate contraception (estrogen contraception or no contraception) in women of childbearing age or breastfeeding woman\n* PS\\>2 or life expectancy \\\u003C12 months.",{"count":140,"type":20},1308,[23],"Philadelphia-negative myeloproliferative neoplasms (MPN) are frequent and chronic myeloid malignancies including Polycythemia Vera (PV), essential thrombocythemia (ET), Primary Myelofibrosis (PMF) and Prefibrotic myelofibrosis (PreMF). These MPNs are caused by the acquisition of mutations affecting activation\u002Fproliferation pathways in hematopoietic stem cells. The principal mutations are JAK2V617F, calreticulin (CALR exon 9) and MPL W515. ET or MFP\u002FPreMF patients who do not carry one of these three mutations are declared as triple-negative (3NEG) cases even if they are real MPN cases.\n\nThese diseases are at high risk of thrombo-embolic complications and with high morbidity\u002Fmortality. This risk varies from 4 to 30% depending on MPN subtype and mutational status.\n\nIn terms of therapy, all patients with MPNs should also take daily low-dose aspirin (LDA) as first antithrombotic drug, which is particularly efficient to reduce arterial but not venous events.\n\nDespite the association of a cytoreductive drug and LDA, thromboses still occur in 5-8% patients\u002Fyear.\n\nAll these situations have been explored in biological or clinical assays. All of them could increase the bleeding risk. We should look at different ways to reduce the thrombotic incidence: Direct Oral Anticoagulants (DOAC)? In the general population, in medical or surgical contexts, DOACs have demonstrated their efficiency to prevent or cure most of the venous or arterial thrombotic events.\n\nAt the present time, DOAC can be used in cancer populations according to International Society on Thrombosis and Haemostasis (ISTH) recommendations, except in patients with cancer at high bleeding risk (gastro-intestinal or genito-urinary cancers). Unfortunately, in trials evaluating DOAC in cancer patients, most patients have solid rather than hematologic cancers (generally less than 10% of the patients, mostly lymphoma or myeloma).\n\nIn cancer patients, DOAC are also highly efficient to reduce the incidence of thrombosis (-30 to 60%), but patients are exposed to a higher hemorrhagic risk, especially in digestive cancer patients.\n\nIn the cancer population, pathophysiology of both thrombotic and hemorrhagic events may be quite different between solid cancers and MPN. If MPN patients are also considered to be cancer patients in many countries, the pathophysiology of thrombosis is quite specific (hyperviscosity, platelet abnormalities, clonality, specific cytokines…) and they are exposed to a lower risk of digestive hemorrhages. It is thus difficult to extend findings from the \"general cancer population\" to MPN patients.\n\nUnfortunately, only scarce, retrospective data regarding the use of DOAC in MPNs are available data.\n\nWe were the first to publish a \"real-life\" study about the use, the impact, and the risks in this population. In this local retrospective study, 25 patients with MPN were treated with DOAC for a median time of 2.1 years. We observed only one thrombosis (4%) and three major hemorrhages (12%, after trauma or unprepared surgery). Furthermore, we have compared the benefit\u002Frisk balance compared to patients treated with LDA without difference.\n\nWith the increasing evidences of efficacy and tolerance of DOAC in large cohorts of patients including cancer patients, with their proven efficacy on prevention of both arterial and venous thrombotic events and because of the absence of prospective trial using these drugs in MPN patients, we propose to study their potential benefit as primary thrombotic prevention in MPN.",[122,26,144,145,146],"Prefibrotic\u002FEarly Primary Myelofibrosis","JAK2 V617F","High-risk Patients",[148,149,150],"Venous ThromboEmbolism","Arterial Thrombosis","Hemorrhage","2026-03-18",{"date":153,"type":36},"2026-03-20",{"date":155,"type":36},"2022-07-13",{"date":157,"type":20},"2027-07-13",{"name":159,"class":80},"University Hospital, Brest",42,{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":168,"targetDuration":4,"studyType":21,"phases":170,"briefSummary":171,"conditions":172,"keywords":179,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":191},"100384169","phase-2-decitabine-with-ruxolitinib-fedratinib-or-pacritinib-for-the-treatment-of-acceleratedblast-phase-myeloproliferative-neoplasms-100384169","NCT04282187","Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated\u002FBlast Phase Myeloproliferative Neoplasms","A Phase 2 Trial Investigating Decitabine in Combination With a JAK-Inhibitor as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant in Patients With Accelerated\u002FBlast Phase Myeloproliferative Neoplasms","Inclusion Criteria:\n\n* Age \\>= 18 years\n* History of MPN as defined by the 2016 World Health Organization criteria, with now pathologically confirmed \\>= 5% blasts in the bone marrow or peripheral blood. Prior MPNs could include polycythemia vera, essential thrombocythemia, primary myelofibrosis, secondary myelofibrosis, MPN unclassifiable, MDS\u002FMPN overlap\n* Outside diagnostic material is acceptable as long as peripheral blood and\u002For bone marrow slides are reviewed at the study institution by pathology. Flow cytometric analysis of peripheral blood and\u002For bone marrow should be performed according to institutional practice guidelines\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2 or Karnofsky \\>= 60%\n* Serum creatinine clearance \\>= 50 ml\u002Fmin calculated by the Cockcroft-Gault Equation (assessed within 14 days of study day 1)\n* Total bilirubin =\\\u003C 3 unless due to Gilbert's disease or hemolysis (total bilirubin \\> 3 is allowable if thought due to Gilbert's disease, hemolysis, or MPN disease) (assessed within 14 days of study day 1)\n* Aspartate aminotransferase (AST)\u002Falanine aminotransferase (ALT) \\\u003C 3 x upper limit of normal (ULN) unless thought to be due to MPN disease process (AST\u002FALT \\> 3 is allowable if thought due to MPN disease) (assessed within 14 days of study day 1)\n* For patient receiving fedratinib, thiamine level should be above the laboratory lower limit of normal (\\>= 70 nmol\u002FL in the University of Washington \\[UW\\]\u002FSeattle Cancer Care Alliance \\[SCCA\\] lab). If it is low, it may be repleted but should be rechecked and demonstrated to normalize prior to initiation of therapy\n* Patient is considered a potential transplant candidate. The attending\u002Ftreating physician will determine transplant candidacy at the time of consent\n* The use of hydroxyurea prior to study registration is allowed. Patients with symptoms\u002Fsigns of hyperleukocytosis, white blood count (WBC) \\> 100,000\u002FuL, or with concern for other complications of high tumor burden or leukostasis (e.g. hypoxia, disseminated intravascular coagulation) can be treated with leukapheresis or may receive up to 2 doses of cytarabine (up to 500 mg\u002Fm\\^2 \u002Fdose) anytime prior to enrollment\n* Capable of providing valid informed consent\n\nExclusion Criteria:\n\n* Previous treatment with chemotherapy (e.g. hypomethylating agents or cytarabine-based regimens) for MPN with \\>= 5% blasts in the blood or marrow. Prior temporary measures to control blood counts is allowed. Prior treatment with hydroxyurea, interferons or JAK inhibitor therapy is allowed\n* Active systemic fungal, bacterial, viral, or other infection, unless disease is under treatment with anti-microbials and\u002For controlled or stable (e.g. if specific, effective therapy is not available\u002Ffeasible or desired \\[e.g. chronic viral hepatitis, human immunodeficiency virus (HIV)\\])\n* Known hypersensitivity to any study drug\n* Females who are pregnant or breastfeeding\n* Treatment with any other anti-MDS\u002Fleukemia investigational agent within 2 weeks of start of study drugs\n* For patients planning to receive fedratinib: concurrent use of strong and moderate CYP3A4 inducers or dual CYP3A4 and CYP2C19 inhibitors that cannot be discontinued\n* For patients planned to receive ruxolitinib AND platelets \\\u003C 50,000\u002Fmm\\^2: concurrent use of a strong CYP3A4 inhibitor that cannot be discontinued\n* For patients planned to receive pacritinib, corrected QT interval (QTc) \\> 480 msec (changing of medications\u002Fsupplementing electrolytes is allowed to determine if this helps QTc reduce to \\\u003C 480 msec)\n* For patients planned to receive pacritinib, concurrent use of medications that are CYP1A2, CYP3A4, P-gp, BCRP, OCT1 substrates that cannot be discontinued",{"count":169,"type":20},25,[116],"This phase II trial studies how well decitabine with ruxolitinib, fedratinib, or pacritinib works before hematopoietic stem cell transplant in treating patients with accelerated\u002Fblast phase myeloproliferative neoplasms (tumors). Drugs used in chemotherapy, such as decitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ruxolitinib, fedratinib, and pacritinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving chemotherapy before a donor hematopoietic stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. The donated stem cells may also replace the patient's immune cells and help destroy any remaining cancer cells. Decitabine, with ruxolitinib, fedratinib, or pacritinib may work better than multi-agent chemotherapy or no pre-transplant therapy, in treating patients with accelerated\u002Fblast phase myeloproliferative neoplasms.",[173,26,120,174,175,176,122,177,178],"Acute Myeloid Leukemia","Myelodysplastic\u002FMyeloproliferative Neoplasm","Myeloproliferative Neoplasm","Myeloproliferative Neoplasm, Not Otherwise Specified","Primary Myelofibrosis","Secondary Myelofibrosis",[180,181],"Myeloid and Monocytic Leukemia","Other Hematopoietic","2026-03-11",{"date":184,"type":36},"2026-03-16",{"date":186,"type":36},"2020-03-24",{"date":188,"type":20},"2026-11-11",{"name":190,"class":80},"University of Washington",1,{"id":193,"slug":194,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":196,"acronym":4,"eligibilityCriteria":197,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":198,"targetDuration":4,"studyType":21,"phases":200,"briefSummary":202,"conditions":203,"keywords":205,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":81},"100448738","phase-1-an-optimal-dose-finding-study-of-n-acetylcysteine-in-patients-with-myeloproliferative-neoplasms-100448738","NCT05123365","An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms","Inclusion Criteria:\n\n* ≥18 years of age\n* Have a diagnosis of essential thrombocythemia (ET), polycythemia vera (PV), or myelofibrosis (MF) according to the 2016 WHO criteria\n* Has not taken interferon-alpha or a JAK inhibitor (such as ruxolitinib or fedratinib) for treatment of MPN in the past 28 days before enrollment.\n* May continue on current MPN treatment, including aspirin, hydroxyurea, or anagrelide. Therapeutic phlebotomies should continue per the patient's usual regimen.\n* Has not taken N-Acetylcysteine (N-AC) or preparations containing N-AC in the past 28 days before enrollment.\n* Baseline MPN-TSS score of ≥ 10 at the time of enrollment.\n* Peripheral blast count \\\u003C10% during Screening.\n* Free of other active or metastatic malignancies other than localized skin cancer.\n* Amenable to blood draws and symptom assessments.\n* Agree to the use of contraceptives. Female subjects of childbearing potential and their male partners, or male subjects who have female partners of childbearing potential, should both use an effective contraception method during the study and continue to use contraception for 60 days after the last dose of study drug.\n\nExclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) questionnaire score of ≥3\n* Currently pregnant or planning on being pregnant within the study period.\n* Currently breastfeeding.\n* Known uncontrolled active viral or bacterial infection.\n* Significant impairment of major organ function defined as\n\n  1. Serum creatinine clearance less than 50 ml\u002Fmin (calculated with Cockroft-Gault formula).\n  2. Bilirubin more than 1.5 mg\u002Fdl except for Gilbert's disease. ALT or AST more than 2X upper normal limit or has radiologic evidence of liver cirrhosis.\n  3. Platelets \\\u003C 100 × 10\\^9\u002FL\n  4. Hgb \\\u003C 10 g\u002FdL\n  5. ANC \\\u003C 0.75 × 10\\^9\u002FL\n* Known history of allergic reaction to N-AC.",{"count":199,"type":20},27,[201,116],"PHASE1","This is a phase I\u002FII study evaluating the optimal dose of N-acetylcysteine (N-AC) in patients with myeloproliferative neoplasms (MPN).",[175,204,26,122,121],"MPN",[204,175,206,122,121],"Essential Thrombocytemia","2026-03-06",{"date":209,"type":36},"2026-03-10",{"date":211,"type":36},"2022-01-03",{"date":213,"type":20},"2026-11-15",{"name":215,"class":80},"University of California, Irvine",{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":220,"acronym":221,"eligibilityCriteria":222,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":223,"targetDuration":4,"studyType":21,"phases":225,"briefSummary":227,"conditions":228,"keywords":231,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":243},"100434814","interest-of-calr-allele-burden-in-diagnosis-and-follow-up-of-patients-with-calr-mutated-myeloproliferative-syndromes-calrsuivi-100434814","NCT04942080","Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI)","CALRSUIVI","Inclusion Criteria:\n\n* adults (age ≥18 years),\n* affiliated to the national social security system,\n* with CALR mutated myeloproliferative neoplasm diagnosed between 2006 - 2020,\n* for which at least one sample is available at the time of diagnosis or before cytoreductive treatment,\n* who signed the consent to participate in the study,\n* included, or consenting to be included, in the national clinical-biological database of France Intergroupe Syndrome Myéloprolifératifs (FIM).\n\nExclusion Criteria:\n\n* patient with another active hematological disease or cancer at the time of diagnosis,\n* person subject to legal protection scheme or incapable of giving consent.",{"count":224,"type":20},260,[226],"NA","Prospective study to evaluate the relevance of CALR allele burden monitoring as a molecular marker of disease progression.",[175,26,229,230],"Primary Myelofibrosis, Prefibrotic Stage","Primary Myelofibrosis, Fibrotic Stage",[232,175,26,177,233],"CALR","Thrombocytosis","2026-03-05",{"date":207,"type":36},{"date":237,"type":36},"2021-10-28",{"date":239,"type":20},"2030-04-28",{"name":241,"class":242},"University Hospital, Angers","OTHER_GOV",10,{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":4,"eligibilityCriteria":250,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":251,"targetDuration":4,"studyType":21,"phases":253,"briefSummary":254,"conditions":255,"keywords":256,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":267},"100411950","phase-2-ruxolitinib-in-thrombocythemia-and-polycythemia-vera-100411950","NCT04644211","Ruxolitinib in Thrombocythemia and Polycythemia Vera","A Phase 2 Study Of Ruxolitinib In Low-Risk Essential Thrombocythemia And Polycythemia Vera With Significant Symptom Burden","Inclusion Criteria:\n\n* Patients who have been diagnosed with essential thrombocythemia or polycythemia vera by World Health Organization 2016 diagnostic criteria.\n* Patients with essential thrombocythemia must be very low (no history of thrombosis, age \\\u003C60, and no JAK2 mutation), low (no history of thrombosis, age \\\u003C60, presence of JAK2 mutation), or intermediate risk (no history of thrombosis, age \\>60, no JAK2 mutation) by IPSET criteria. Patients with polycythemia vera must be low risk (no history of thrombosis and age \\\u003C60) by NCCN guidelines.\n* Patients with an MPN-SAF TSS (MPN-10) score \\>10 AND at least one individual feature \\>5 documented on a separate visit within 3 months prior to study registration, as documented in the clinical record or obtained by clinician. If not previously documented in the electronic medical record, participants must be blinded to purpose of MPN SAF TSS scoring for eligibility determination. Average daily MPN-SAF TSS (MPN-10) score must remain \\>10 with any individual feature \\>5 for the week-long baseline assessment prior to ruxolitinib initiation.\n* Patients who have previously received or are receiving cytoreductive therapy (i.e. hydroxyurea, anagrelide, interferon) are eligible for the study if therapy was used for the indication of symptom control, or if therapy was used for pre-operative control of blood counts. If a subject is still receiving cytoreductive therapy at the time of screening and enrollment, there will be a wash-out period from prior cytoreductive therapy at least 7 days prior to ruxolitinib initiation.\n* Age ≥18 years.\n* ECOG performance status ≤2 (Karnofsky ≥60%)\n* Participants must have adequate organ and marrow function as defined below:\n\n  * leukocytes ≥3,000\u002FmcL\n  * absolute neutrophil count ≥1,500\u002FmcL\n  * platelets ≥100,000\u002FmcL\n  * total bilirubin ≤ institutional upper limit of normal (ULN)\n  * AST(SGOT)\u002FALT(SGPT) ≤3 × institutional ULN\n  * creatinine ≤ institutional ULN OR glomerular filtration rate (GFR) ≥60 mL\u002Fmin\u002F1.73 m2 unless data exists supporting safe use at lower kidney function values, no lower than 30 mL\u002Fmin\u002F1.73 m2\n* Participants with a prior or concurrent malignancy not receiving treatment for concurrent cancer diagnosis and\u002For prior concurrent malignancy within 5 years except for basal cell carcinoma or squamous cell carcinoma of the skin.\n* For participants with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.\n* For participants with evidence of chronic human immunodeficiency virus (HIV) infection, they must be negative for HBV DNA, HCV RNA, or hepatitis B surface antigen (BsAg) on suppressive therapy, if indicated.\n* Participants must be previously vaccinated with the Herpes Zoster (Shingles) vaccine or must be willing to start prophylactic Acyclovir 400 mg twice daily (BID) or suitable alternative for duration of treatment with ruxolitinib.\n* Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, participants should be class 2B or better.\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Essential thrombocythemia patients who are high risk by IPSET-R criteria (age \\> 60 with JAK2 V617F mutation and\u002For history of thrombosis).1 Polycythemia vera patients who are high risk by NCCN guidelines (age \\> 60 and\u002For history of thrombosis).\n* Patients with \\>5% blasts on baseline marrow exam or at any other time in peripheral blood\n* Participants who are receiving any other investigational agents.\n* Participants with a history of splenectomy. Participants may still be eligible after discussion with and approval by the Overall PI, however.\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to ruxolitinib or excipients of ruxolitinib.\n* Participants requiring any medications or substances that are strong inhibitors or 3A4 isozyme are ineligible. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference. As part of the enrollment\u002Finformed consent procedures, the participant will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the participant is considering a new over-the-counter medicine or herbal product.\n* Participants with uncontrolled intercurrent illness.\n* Participants with inadequate liver or renal function at screening as evidenced by lab values not meeting criteria\n* Participants with psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Pregnant women are excluded from this study because ruxolitinib is a Class C agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with ruxolitinib, breastfeeding should be discontinued if the mother is treated with ruxolitinib.\n* The effects of ruxolitinib on the developing human fetus are unknown. Pregnant women and subjects of childbearing potential who are unwilling to take appropriate precautions to avoid becoming pregnant or fathering a child are ineligible. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of ruxolitinib administration.",{"count":252,"type":20},60,[116],"This research is being done to see if the drug ruxolitinib is effective in reducing the symptoms caused by low-risk essential thrombocythemia (ET) and polycythemia vera (PV).\n\n\\- This research study involves the study drug Ruxolitinib.",[26,122],[26,122,257],"Sympton Burden","2026-01-07",{"date":260,"type":36},"2026-01-08",{"date":262,"type":36},"2022-03-21",{"date":264,"type":20},"2034-07",{"name":266,"class":80},"Massachusetts General Hospital",4,{"id":269,"slug":270,"hasResults":11,"nctId":271,"briefTitle":272,"officialTitle":273,"acronym":274,"eligibilityCriteria":275,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":276,"targetDuration":4,"studyType":21,"phases":278,"briefSummary":279,"conditions":280,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":282,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":289},"100543882","functional-and-phenotypic-characterization-of-monocytes-in-myeloproliferative-syndromes-100543882","NCT06361641","Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes","Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes-PHEMOP","PHEMOP","Inclusion Criteria:\n\n* Diagnosis of PV, ET, pre-myelofibrosis or primary myelofibrosis according to WHO 2022 criteria (including BOM for ET, premyelofibrosis and primary myelofibrosis)\n* Patient who has not received treatment specific to hemopathy at the time of sampling\n* Obtaining the signature of consent to participate in the study\n* Patient having consented to be included in the \"Malignant Hemopathy\" collection of Angers University Hospital and in FIMBANK database\n\nExclusion Criteria:\n\n* Person not affiliated to a social security scheme or beneficiary of such a scheme\n* Patient with another hemopathy or another active cancer at the time of diagnosis\n* Minor patient at diagnosis (\\\u003C 18 years old)\n* Patient not capable or without agreement from the guardian or legal representative",{"count":277,"type":20},70,[226],"Prospective study for functional and phenotypic characterization of monocytes in philadelphia-negative myeloproliferative neoplasms",[175,122,26,177],"2025-12-02",{"date":283,"type":36},"2025-12-08",{"date":285,"type":36},"2024-05-29",{"date":287,"type":20},"2028-10-19",{"name":241,"class":242},3,{"id":291,"slug":292,"hasResults":11,"nctId":293,"briefTitle":294,"officialTitle":295,"acronym":4,"eligibilityCriteria":296,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":297,"targetDuration":4,"studyType":21,"phases":298,"briefSummary":299,"conditions":300,"keywords":301,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":314},"100558539","phase-2-peginterferon--2b-injection-for-hydroxyurea-resistant-or-intolerant-et-100558539","NCT06552429","Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ET","A Phase 2 Multicenter, Randomized, Open-label Study to Evaluate the Pharmacokinetic, Safety and Efficacy of Peginterferon Alfa-2b Injection in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea.","Inclusion Criteria:\n\n* Male or female subjects, aged greater or equal to 18 years old at screening;\n* Subjects diagnosed as high-risk ET according to the World Health Organization (WHO) 2016 criteria：1) who is older than 60 years and JAK2V617F positive at screening, 2) or who previously suffered from disease-related thrombosis or hemorrhage;\n* Subjects who have previously received HU for ET, and the time interval between the last HU dose and the first dose of the study drug should not be less than 7 days;\n* Interferon treatment-naïve, and for those who have previously received interferon the the time interval between the last dose of interferon and randomization should not be less than 1 month;\n* Patients with confirmed hydroxyurea resistance or intolerant, as at least one of the following criteria is met:\n\n  1. Platelet count remain greater than 600×10\\^9 \u002FL after at least 3 months of HU treatment at a dose ≥2g\u002Fd (dose ≥2.5 g\u002Fd if subject weight \\> 80 kg);\n  2. Platelet count greater than 400\\*10\\^9\u002FL while white blood cell (WBC) count lower than 2.5\\*10\\^9\u002FL, or platelet count greater than 400\\*10\\^9 \u002FL while hemoglobin lower than 100 g\u002FL at any dose of HU;\n  3. Presence of HU-related toxicities at any dose of HU: e.g. ulcers in legs, or any unacceptable skin mucosal manifestations or fever;\n* Platelet counts \\> 450\\*10\\^9\u002FL at screening;\n* Neutrophil count ≥1.0\\*10\\^9\u002FL at screening;\n* Haemoglobin ≥11 g\u002FdL at screening for males and 10 g\u002FdL for females at screening;\n* There is no serious function damage in liver and kidney: total bilirubin ≤1.5 upper limit of normal (ULN), alanine aminotransferase≤2.0 ULN, aspartate aminotransferase≤2.0 ULN, prothrombin time is prolonged by less than 4 seconds, Creatinine clearance ≥50 mL\u002Fmin (according to Cockcroft-Gault formula) at screening;\n* Both male and female subjects must agree take an appropriate contraceptive method, including:\n\n  1. Male subjects: must agree to use reliable contraception from inform consent until 6 months following the last dose of the study drug.\n  2. Female subjects: Must meet at least one of the following conditions:\n\n  i) Women without childbearing potential; ii) Women of childbearing potential: no pregnant or breastfeed, negative in blood pregnancy test within 4 days prior to the first dosing, and must agree to use reliable contraception from inform consent until 6 months following the last dose of the study drug;\n* Subjects understand the objective, characteristic, method and possible adverse reactions of the study, voluntarily participate in this study, and sign informed consent.\n\nExclusion Criteria:\n\n* History of any other myeloproliferative tumors, or evidence of the presence of any other myeloproliferative tumors;\n* Contraindications or hypersensitivities to interferons of any of its excipients;\n* Severe medical conditions or serious comorbidities that the investigators determined could jeopardize the safety or protocol adherence, e.g. New York Heart Association \\[NYHA\\] Class III-IV, congestive heart failure, symptomatic arrhythmias，pulmonary hypertension;\n* History of major organ transplantation;\n* Documented autoimmune disease or history of autoimmune disease at screening, e.g. medication un-controlled thyroid dysfunction, autoimmune hepatitis, idiopathic thrombocytopenic purpura, scleroderma, psoriasis, or any autoimmune arthritis;\n* Clinically significant pulmonary infiltration, infectious pneumonia, and non-infectious pneumonia at screening that, in the investigator's opinion, would jeopardize the safety of the subject or their compliance with the protocol;\n* Infection with systemic clinical manifestations at screening, e.g., bacteria, fungi, human immunodeficiency virus, excluding hepatitis B and\u002For C;\n* Evidence of severe retinopathy, e.g., cytomegalovirus retinitis, symptomatic macular degeneration, or clinically significant eye disease, e.g. due to diabetes mellitus or hypertension;\n* Diagnosed clinically significant depression or a history of depression and, in the investigator's opinion, previous suicide attempts or at any risk of suicide at screening;\n* Diagnosed clinically significant neurological disease or a history of clinically significant neurological disease, except for a history of stable cerebral thrombosis or cerebral hemorrhage;\n* History of any malignancy within 5 years (except stage 0 chronic lymphocytic leukemia, basal cell carcinoma, squamous cell carcinoma, and superficial melanoma);\n* A history of alcohol or drug abuse within 1 year;\n* Have used any investigational drug within 4 weeks prior to first dose of investigational drug, or not recovered from the effects of prior investigational drug administration;\n* Other situations that, in the investigator's opinion, not appropriate for inclusion.",{"count":199,"type":20},[116],"This is a multicenter, randomized, open-label Phase 2 clinical study. It is aimed to enroll 27 essential thrombocytopenia (ET) patients who are resistant to or intolerant of hydroxyurea(HU). Eligible patients will be randomized to receive either Peginterferon α-2b 135 mcg or Peginterferon α-2b 180 mcg at a ratio of 1:2, and all subjects will go through a target treatment period (Weeks 1 \\~ Week 48), an extension treatment period (Weeks 49 \\~ Week 96) and a follow-up period (Weeks 97 \\~ Week 100). Pharmacokinetics, safety, efficacy will be evaluated.",[26],[26,302,303,304],"Peginterferon α-2b","hydroxyurea resistant","hydroxyurea intolerant","2025-11-13",{"date":307,"type":36},"2025-11-17",{"date":309,"type":36},"2024-08-29",{"date":311,"type":20},"2027-09",{"name":313,"class":43},"Xiamen Amoytop Biotech Co., Ltd.",8,{"id":316,"slug":317,"hasResults":11,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":4,"eligibilityCriteria":321,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":322,"targetDuration":4,"studyType":21,"phases":324,"briefSummary":325,"conditions":326,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":340,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":191},"100441709","phase-2-two-step-haplo-with-radiation-conditioning-100441709","NCT05031897","Two Step Haplo With Radiation Conditioning","A 2 Step Approach to Haploidentical Transplant Using Radiation-Based Reduced Intensity Conditioning","Inclusion Criteria:\n\n* Radiation-based cohort diagnoses:\n\n  * Acute myeloid leukemia\n  * Acute lymphoid leukemia in remission\n  * Myelodysplasia (MDS)\n  * Chronic lymphocytic leukemia (CLL) with no or minimal lymph node involvement\n  * Multiple myeloma\n  * Chronic myeloid leukemia\n  * Myelofibrosis\n  * Myeloid malignancy not otherwise specified\n  * Chronic myelomonocytic leukemia\n  * Essential thrombocytopenia or polycythemia vera\n  * T cell leukemia\n  * T cell lymphoma without significant lymph node disease burden\n  * Any hematological malignancy or dyscrasia not cited above in which HSCT is potentially curable\n  * Any patient who has a hematological disease that would normally be treated on a myeloablative study, but is prevented from doing so by factors in their past medical history. Examples are patients with previous treatment with radiation therapy precluding total-body irradiation (TBI), or a past history of myeloablative therapy, precluding a 2nd myeloablative regimen.\n  * Patients must have a donor who is one-haplotype mismatched (number of mismatches in either direction not considered)\n* Chemotherapy-based cohort diagnoses:\n\n  * Hodgkin or non-Hodgkin lymphoma\n  * Small lymphocytic lymphoma\u002FCLL\n  * Any other diagnosis in which chemotherapy is thought to be superior to radiotherapy for treatment of the disease\n  * Hematological malignancy in patients who cannot receive \\> 2 Gy radiation\n  * Aplastic anemia and other non-malignant hematologic dyscrasias\n  * Patients must have a donor who is one-haplotype mismatched (number of mismatches in either direction not considered)\n* Human leukocyte antigen (HLA) identical cohort diagnoses:\n\n  \\* Patients in this group will be treated in parallel to the radiation-based cohort or the chemotherapy-based group based on what category their diagnosis falls into. However, these patients will have HLA identical related donors (one-antigen cross-over event included).\n* Left ventricular ejection fraction of \\>= 50%\n* Diffusion lung capacity of oxygen \\>= 50% and forced expiratory volume at 1 second \\>= 50% of predicted corrected for hemoglobin\n* Serum bilirubin =\\\u003C 1.8\n* Aspartate aminotransferase or alanine aminotransferase =\\\u003C 2.5 x upper limit of normal\n* Creatinine clearance of \\>= 60 mL\u002Fmin\n* Patients must have adequate Karnofsky performance status (KPS) and Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI) scores:\n\n  * Patients \\\u003C age 60 years must have a KPS of \\>= 60% and an HCT-CI score of 5 or less\n  * Patients aged 60 to 65 years must have a KPS of \\>= 60% and an HCT-CI score of 4 or less\n  * Patients aged 66 to 69 years must have a KPS of 90% and an HCT-CI score of 3 or less\n  * Patients aged 70 years or more must have a KPS of 90% and an HCT-CI score of 2 or less\n  * (Patients with greater than the allowable HCT-CI points for age can be enrolled for trial with approval of the principal investigator (PI) and at least 1 co-investigator (CI) not on the primary care team of the patient). This is an adjustment to account for healthy patients who meet the spirit of this protocol but have histories that result in higher than guideline HCT-CI points. An example is a patient with a solid tumor malignancy in their remote history (adds 3 points to HCT-CI total) where the treatment for the malignancy occurred years to decades before and there has been complete recovery of toxicities\n* Patients must be willing to use contraception if they have childbearing potential\n* Patient or patient's guardian is able to give informed consent\n* Patients should have a life expectancy of \\>= 6 months for reasons other than their underlying hematologic\u002Foncologic disorder\n* Patients with evidence of another malignancy, exclusive of a skin cancer that requires only local treatment, should not be enrolled on this protocol\n* Patients should not be:\n\n  * Human immunodeficiency virus positive\n  * Have active involvement of the central nervous system with malignancy. This can be documented by a normal neurological exam, magnetic resonance imaging (MRI) of the head, and\u002For a negative cerebral spinal fluid analysis\n* Pregnant or breastfeeding",{"count":323,"type":20},63,[116],"This phase II clinical trial evaluates whether a modified modality of conditioning reduces treatment-related mortality (TRM) in patients who undergo a hematopoietic stem cell transplant (HSCT) for a hematological malignancy. HSCT is a curative therapy for many hematopoietic malignancies, however this regimen results in higher rates of TRM than other forms of treatment. In recent years, less intense conditioning regimens with radiation and chemotherapy prior to HSCT have been developed. Radiation therapy uses high energy sources to kill cancer cells and shrink tumors while chemotherapy drugs like fludarabine and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This study evaluates whether a two-step approach with lower-intensity regimens of these treatments prior to HSCT reduces the rate of TRM.",[327,173,328,329,330,331,332,26,333,334,335,120,121,336,337,122,338],"Acute Lymphoblastic Leukemia","Adult T-Cell Leukemia\u002FLymphoma","Aplastic Anemia","Chronic Lymphocytic Leukemia","Chronic Myeloid Leukemia, BCR-ABL1 Positive","Chronic Myelomonocytic Leukemia","Hematopoietic and Lymphatic System Neoplasm","Hodgkin Lymphoma","Multiple Myeloma","Myeloid Neoplasm","Non-Hodgkin Lymphoma","Small Lymphocytic Lymphoma","2025-10-28",{"date":341,"type":36},"2025-10-30",{"date":343,"type":36},"2021-10-25",{"date":345,"type":20},"2032-04",{"name":347,"class":80},"Thomas Jefferson University",{"id":349,"slug":350,"hasResults":11,"nctId":351,"briefTitle":352,"officialTitle":353,"acronym":4,"eligibilityCriteria":354,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":355,"targetDuration":4,"studyType":21,"phases":357,"briefSummary":358,"conditions":359,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":365,"completionDateStruct":367,"leadSponsor":368,"locationsCount":370},"100545172","phase-1-a-study-of-glb-001-in-patients-with-myeloid-malignancies-100545172","NCT06378437","A Study of GLB-001 in Patients With Myeloid Malignancies","A Phase 1, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of GLB-001 in Patients With Myeloid Malignancies","Inclusion Criteria:\n\n* Study participants must understand and voluntarily sign a written informed consent form (ICF) prior to any study-related assessments\u002Fprocedures being performed.\n* Study participants is ≥18 years of age at the time of signing the ICF.\n* Study participants with confirmed diagnosis of relapsed or refractory or intolerant myeloid malignancies including PV, ET, primary myelofibrosis (PMF), MDS and AML according to 2022 World Health Organization (WHO) criteria classification, and post-polycythemia vera myelofibrosis (post-PV MF) and post-essential thrombocythemia myelofibrosis (post-ET MF) according to the 2013 IWG-MRT criteria.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0,1 or 2.\n* Life expectancy \\> 3 months.\n* Good performance of major organs, including hematology, liver and kidney function, and coagulation. etc.\n* Study participants are willing and able to adhere to the study visit schedule and other protocol requirements.\n\nExclusion Criteria:\n\n* Study participants with acute promyelocytic leukemia (APL).\n* Receipt of following anticancer medications\u002Ftherapies prior to the first dose of GLB-001: (1) study participants with PV or ET who received treatment with hydroxyurea within 2 days prior to the first dose, or any other treatment for PV or ET within 7 days prior to first dose of GLB-001, (2) study participants with MF who received any type of treatment for MF within 14 days prior to the first dose, such as chemotherapy, immunotherapy, radiotherapy and erythropoietin, androgens, thrombopoietin or granulocyte colony-stimulating factor, (3) study participants with LR-MDS who received any type of treatment for MDS within 14 days prior to the first dose, (4) study participants with HR-MDS or AML who received chimeric antigen receptor T cell therapy (CAR-T) or other biologic therapy within 28 days prior to the first dose of GLB-001, or received any other anticancer therapies within 14 days prior to the first dose of GLB-001.\n* Receipt of any other investigational drug study within 28 days or 5 half-lives of that study drug before the first dose of GLB-001.\n* Study participants with unresolved clinically significant non-hematologic toxicities that were ≥ Grade 1 or failed to recover to baseline levels following prior anticancer therapies (with the exception of alopecia or skin hyperpigmentation).\n* Study participants who are scheduled to receive other anticancer therapies or other investigational drugs during the study period.\n* Study participants with active acute or chronic graft versus host disease (GVHD) requiring systemic immunosuppressive therapy.\n* Receipt of autologous stem cell transplantation (ASCT) within the last 3 months prior to the first dose of GLB-001, or allogeneic hematopoietic stem cell transplantation (allo-HSCT) within the last 6 months prior to the first dose of GLB-001.\n* Study participants with known active involvement in central nervous system (CNS).\n* Study participants with peripheral neuropathy ≥ Grade 2 (Graded according to CTCAE version 5.0).\n* Study participants have a history of known malignancy other than the inclusion diagnosis for the past 5 years, with the exception of curatively resected cancer in situ, including cervical carcinoma in situ, basal cell carcinoma of the skin, or prostate cancer in situ, etc.\n* QT interval interval \\> 450 milliseconds (ms) using electrocardiographic (ECG) at screening.\n* Study participants have impaired cardiac function or clinically significant cardiac disease at current or within last 6 months.\n* Study participants with known active infection of hepatitis B virus (HBV) or hepatitis C virus C (HCV).\n* Study participants with known human immunodeficiency virus (HIV) infection.\n* Study participants with known life-threatening or clinical significant uncontrolled active systemic infections unrelated to malignant hematologic diseases.\n* Study participants with a state condition that may alter affects the absorption, distribution, metabolism and excretion of GLB-001 after judgment of the investigator.\n* Medications or supplements that are known to be strong and moderate inhibitors or inducers of cytochrome P-450 isozyme 3A (CYP3A) and\u002For P-glycoprotein (P-gp), or strong inhibitors or inducers of CYP450 isozyme 2C8 (CYP2C8) within 7 days or 5 half-lives prior to the first dose of GLB-001, whichever is shorter prior to the first dose of GLB-001.\n* Study participants who have undergone major surgery within 28 days prior to the first dose of the GLB-001, or unability to recover from effects of surgery.\n* Pregnant or lactating women.\n* Study participants who have cognitive impairment due to any psychiatric or neurological condition, including epilepsy and dementia, may limit their understanding, performance, and study compliance with the ICF.\n* Study participants, in the opinion of the Investigator, who are unsuitable to participate in the study.",{"count":356,"type":20},108,[201],"Study GLB-001-02 is a phase 1, open-label clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of GLB-001 in study participants with relapsed or refractory or intolerant myeloid malignancies including polycythemia vera (PV), essential thrombocythemia (ET), myelofibrosis (MF), lower-risk myelodysplastic syndrome (LR-MDS), higher-risk myelodysplastic syndromes (HR-MDS), and acute myeloid leukemia (AML). This study consists of 3 parts, dose escalation (Phase 1a), dose exploration (Phase 1b) and dose expansion (Phase 1c). Dose escalation (Phase 1a) and dose exploration (Phase 1b) will evaluate the safety, tolerability, PK, PD and preliminary efficacy of GLB-001, administered orally, in study participants with PV\u002FET, or study participants with MF\u002FLR-MDS\u002FHR-MDS\u002FAML, respectively. Dose expansion (Phase 1c) will be followed to determine the relationships among dose, exposure, toxicity, tolerability and clinical activity, to identify minimally active dose, and to select the recommended dose(s) for phase 2 study. Approximately 108 study participants may be enrolled in the study.",[122,26,121,360,173,361],"Myelodysplastic Syndromes","Myeloid Malignancy","2025-08-17",{"date":364,"type":36},"2025-08-19",{"date":366,"type":36},"2024-05-24",{"date":77,"type":20},{"name":369,"class":43},"Hangzhou GluBio Pharmaceutical Co., Ltd.",14,{"id":372,"slug":373,"hasResults":11,"nctId":374,"briefTitle":375,"officialTitle":376,"acronym":4,"eligibilityCriteria":377,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":378,"targetDuration":4,"studyType":21,"phases":379,"briefSummary":380,"conditions":381,"keywords":382,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":386,"lastUpdatePostDateStruct":387,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":393,"locationsCount":191},"100441218","phase-1-mutant-calr-peptide-based-vaccine-in-patients-with-mutated-calr-myeloproliferative-neoplasm-100441218","NCT05025488","Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm","A Phase I Open Label Peptide Based Vaccine in Patients With Myeloproliferative Neoplasm Harboring CALR Mutations","Inclusion Criteria:\n\n* Subjects must be ≥18 years of age at the time of signing the informed consent form.\n* Confirmed diagnosis of chronic phase MPN:\n* Previously treated or relapsed\u002Frefectory high risk ET\n* Low to intermediate 1 risk (DIPSS 0-1) PMF or ET-MF\n* Verified mutation in CALR exon 9\n* PS ≤ 2\n* Adequate organ function:\n\n  * Absolute neutrophil count ≥ 1000\u002Fmm3,\n  * Platelet count ≥ 50,000\u002Fmm3,\n  * Creatinine ≤ 2.5 mg\u002FdL,\n  * Total bilirubin ≤ 2 mg\u002FdL, (except in patients with Gilbert Syndrome who can have total bilirubin \\\u003C 3.0 mg\u002FdL)\n  * Transaminases \\\u003C 3 times above the upper limits of the institutional normal.\n* Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU\u002FmL within 10 - 14 days prior to starting study medication and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 4 weeks prior to first dose of vaccine. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a condom during sexual contact with a female of childbearing potential even if they have had a successful vasectomy.\n* Ability to understand and the willingness to sign a written informed consent.\n* Ability to adhere to the study visit schedule and all protocol requirements.\n* Subjects receiving cytoreductive therapy with hydroxyurea must be on a stable dose for at least 8 weeks prior to week 1.\n\nExclusion Criteria:\n\n* Other invasive malignancy in the past 3 years except non-melanoma skin cancer, localized cured prostate cancer and early stage breast cancer on HRT.\n* Active autoimmune disease.\n* Uncontrolled serious infection.\n* Known immunodeficiency.\n* Pregnant and breastfeeding women.\n* Not willing to use contraception.\n* Current use of immunosuppressive medications including steroids.\n* Current JAK inhibitor use.\n* Current use of IFN (use of anagrelide is permitted).\n* Treatment with other experimental drugs within 30 days of week 1.\n* Treatment with any MPN directed therapy unless otherwise noted within 5 half-lives of week 1.\n* Any significant psychiatric\u002Fmedical condition per investigators judgment.",{"count":243,"type":20},[201],"The primary objective of this study is to assess the safety and tolerability of administrating mutated-CALR peptide Vaccine to patients with MPN. The researchers plan to enroll 10 patients over a 12 month period. Maximum length of participation in 80 weeks. Patients will be asked to complete questionnaires, bone marrow biopsies, research lab collection, and standard of care lab draw. This research will be taking place only at The Mount Sinai Hospital, specifically at the Ruttenberg Treatment Center.",[121,26,204],[232,383,384,29,385],"Vaccine","MF","peptide","2025-04-03",{"date":388,"type":36},"2025-04-06",{"date":390,"type":36},"2023-04-04",{"date":392,"type":20},"2027-03",{"name":394,"class":80},"Marina Kremyanskaya",{"id":396,"slug":397,"hasResults":11,"nctId":398,"briefTitle":399,"officialTitle":400,"acronym":4,"eligibilityCriteria":401,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":402,"targetDuration":4,"studyType":21,"phases":404,"briefSummary":405,"conditions":406,"keywords":407,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":410,"lastUpdatePostDateStruct":411,"startDateStruct":413,"completionDateStruct":415,"leadSponsor":417,"locationsCount":191},"100572543","efficacy-and-safety-of-peginterferon-in-et-and-pv-100572543","NCT06734637","Efficacy and Safety of Peginterferon in ET and PV.","A Single-arm, Single-center Study to Explore the Safety and Efficacy of Pegylated Interferon Alpha in Chinese Patients With ET (Essential Thrombocythemia) and PV (Polycythemia Vera).","Inclusion Criteria:\n\n1. Meet the 2016 WHO diagnostic criteria for ET (Essential Thrombocythemia) and PV (Polycythemia Vera)\n\n   * ET (Essential Thrombocythemia) major criteria:\n\n     1. Platelet count \\> 450 \\* 10\\^9\u002FL; (2) Bone marrow biopsy shows marked megakaryocytic proliferation with increased mature megakaryocyte volume and increased nuclear lobulation. There is no significant granulocytic proliferation, left shift, or erythroid proliferation, with grade 1 fibrosis observed in a few cases; (3) Does not meet the WHO diagnostic criteria for BCR-ABL1+ CML, PV, PMF, MDS, or other myeloproliferative neoplasms; (4) JAK2, CALR, or MPL mutation positive.\n\n        Secondary criteria: (1) Presence of a clonal marker or absence of evidence for reactive thrombocytosis.\n\n        The diagnosis of ET requires the fulfillment of all four main criteria, or the first three main criteria plus one secondary criterion.\n   * PV (Polycythemia Vera) main criteria: (1) Hemoglobin \\> 16.5 g\u002FdL in males, \\> 16 g\u002FdL in females, or Hematocrit \\> 49% in males, \\> 48% in females, or an increase in red cell volume of 25% or more above the normal value; (2) Bone marrow biopsy shows increased cellularity inappropriate for age, with marked erythroid, granulocytic, and megakaryocytic proliferation, and the presence of mature megakaryocytes of varying sizes and morphologies; (3) JAK2 V617F mutation positive or JAK2 exon 12 mutation positive.\n\n   Secondary criteria: Serum Epo (Erythropoietin) level below the lower limit of the normal range.\n\n   The diagnosis of PV requires the fulfillment of three major criteria, or the first two main criteria plus one secondary criterion.\n2. For ET patients, the criteria for cytoreductive therapy must be met, as follows:\n\n(1) For patients without a history of thrombosis: Age ≥ 60 years, regardless of the presence of cardiovascular risk (CVR) or JAK2V617 mutation; Any age with a platelet count \\> 1500 × 109\u002FL. (2) For patients with a history of arterial thrombosis: Any age, regardless of the presence of CVR and JAK2V617 mutation; (3) For patients with a history of venous thrombosis: Any age, regardless of the presence of CVR and JAK2V617 mutation; 3.ECOG score ≤ 2. 4.Cardiac ejection fraction (EF) ≥ 60%. 5.The participant voluntarily signs the informed consent form.\n\nExclusion Criteria:\n\n* Previous treatment with Peginterferon α-2b.\n* ET patients who do not meet the criteria for cytoreductive therapy as per the 2016 Chinese Expert Consensus on Primary Thrombocythemia.\n* Allergy to the active ingredient, α-interferon, or any excipients of this product.\n* History of psychiatric illness, or allergy to interferon.\n* Plasma total bilirubin greater than twice the normal value.\n* Severe cardiac disease, liver insufficiency, chronic kidney disease, and neurological disorders (such as depression or mania).\n* History of other malignant tumors within the past three years.\n* Autoimmune chronic hepatitis.\n* Any condition deemed unsuitable for inclusion by the investigator.",{"count":403,"type":20},40,[226],"This is a single-arm, single-center study aims to recruit 40 participants with Essential Thrombocythemia (ET) and Polycythemia Vera (PV). Eligible participants will receive a subcutaneous injection of Peginterferon α-2b 180 mcg once a week and follow-up，and efficacy and safety will be evaluated.",[26,122],[408,409,302],"Essential thrombocythemia","Polycythemia vera","2024-12-11",{"date":412,"type":36},"2024-12-16",{"date":414,"type":36},"2024-11-20",{"date":416,"type":20},"2027-11-20",{"name":418,"class":80},"Zhenya Hong",{"id":420,"slug":421,"hasResults":11,"nctId":422,"briefTitle":423,"officialTitle":424,"acronym":4,"eligibilityCriteria":425,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":426,"targetDuration":428,"studyType":67,"phases":4,"briefSummary":429,"conditions":430,"keywords":438,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":445,"lastUpdatePostDateStruct":446,"startDateStruct":448,"completionDateStruct":450,"leadSponsor":452,"locationsCount":191},"100267393","myeloproliferative-neoplasms-mpns-patient-registry-100267393","NCT02760238","Myeloproliferative Neoplasms (MPNs) Patient Registry","Clinical and Molecular Epidemiology of Myeloproliferative Neoplasms (MPNs)","Inclusion Criteria:\n\nDiagnosis of one of the following myeloproliferative neoplasms (MPNs):\n\n* Atypical CML (aCML)\n* Chronic eosinophilic leukemia-not otherwise specified (CEL, NOS),\n* Chronic myelomonocytic leukemia (CMML)\n* Chronic neutrophilic leukemia (CNL),\n* Essential thrombocythemia (ET),\n* Juvenile myelomonocytic leukemia (JMML),\n* Mastocytosis, MPN unclassifiable\n* MPN\u002FMDS unclassifiable,\n* Primary myelofibrosis (PMF),\n* Post-essential thrombocythemia myelofibrosis (post-ET MF),\n* Post-polycythemia vera MF (post-PV MF)\n* Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T)\n\nExclusion Criteria:\n\n* None",{"count":427,"type":20},5000,"10 Years","The mandate of this MPN registry is to collect clinical information, including molecular results, from consenting patients with a variety of MPNs at different time points during the course of their disease.",[177,122,26,431,432,433,434,435,436,437],"Mastocytosis","Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative","Leukemia, Myelomonocytic, Juvenile","Chronic Eosinophilic Leukemia-not Otherwise Specified","Myelodysplastic-Myeloproliferative Diseases","Neoplasms","Leukemia, Myelomonocytic, Chronic",[439,440,441,442,443,444,436],"myeloproliferative neoplasm","myelodysplastic syndrome","registry","leukemia","Bone Marrow Diseases","Hematologic Diseases","2024-08-26",{"date":447,"type":36},"2024-08-27",{"date":449,"type":4},"2015-04",{"date":451,"type":20},"2027-10-31",{"name":453,"class":80},"University Health Network, Toronto",{"id":455,"slug":456,"hasResults":11,"nctId":457,"briefTitle":458,"officialTitle":459,"acronym":460,"eligibilityCriteria":461,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":462,"targetDuration":4,"studyType":67,"phases":4,"briefSummary":464,"conditions":465,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":466,"lastUpdatePostDateStruct":467,"startDateStruct":469,"completionDateStruct":471,"leadSponsor":473,"locationsCount":191},"100277897","myeloproliferative-neoplastic-diseases-observatory-from-brest-100277897","NCT02897297","Myeloproliferative Neoplastic Diseases Observatory From Brest","Observatoire Brestois Des Néoplasies Myéloprolifératives","OBENE","Inclusion Criteria:\n\n* Patients with essentiel thrombocythemia, polycythemia vera or primary myelofibrosis\n* Signature of the non-opposition consent form\n\nExclusion Criteria:\n\n* None",{"count":463,"type":20},1000,"All patients diagnosed or followed in Brest University Hospital for Philadelphia negative myeloproliferative neoplasms will be included in this observational study.\n\nMyeloproliferative neoplasms recorded included: polycythemia vera, essential Thrombocythemia and Primary Myelofibrosis.\n\nThis is a not interventional study. Alive patients need to sign a non-opposition consent form.\n\nPatients will be followed until last news (death, change of reference centre...).",[122,26,177],"2024-08-09",{"date":468,"type":36},"2024-08-12",{"date":470,"type":36},"2015-09-01",{"date":472,"type":20},"2025-09-30",{"name":159,"class":80},{"id":475,"slug":476,"hasResults":11,"nctId":477,"briefTitle":478,"officialTitle":479,"acronym":4,"eligibilityCriteria":480,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":481,"targetDuration":428,"studyType":67,"phases":4,"briefSummary":482,"conditions":483,"keywords":486,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":491,"lastUpdatePostDateStruct":492,"startDateStruct":494,"completionDateStruct":496,"leadSponsor":498,"locationsCount":191},"100507083","asian-myeloproliferative-neoplasm-mpn-registry-100507083","NCT05882773","Asian Myeloproliferative Neoplasm (MPN) Registry","Asian Myeloproliferative Neoplasm (MPN) Registry - An Asian Myeloid Working Group (AMWG) Project.","Inclusion Criteria:\n\n1. Age ≥ 18 years old at the time of diagnosis of MPN.\n2. Subject was diagnosed with one of the following disorders according to the 2017 WHO classification (for patients diagnosed before 2017, the bone marrow reports will be re-evaluated according to the 2017 WHO classification):\n\n   1. Polycythaemia vera\n   2. Essential thrombocythemia\n   3. Primary myelofibrosis, pre-fibrotic\u002Fearly stage\n   4. Primary myelofibrosis, overt fibrotic stage\n   5. Post-polycythaemia vera myelofibrosis\n   6. Post-essential thrombocythaemia myelofibrosis\n   7. MPN-unclassifiable\n3. All subjects need to provide informed consent.\n\nExclusion Criteria:\n\nA subject will not be eligible if he\u002Fshe meets any of the following criteria:\n\n1\\. Subject was diagnosed with myelodysplastic syndrome, myelodysplastic syndrome\u002Fmyeloproliferative neoplasm, or chronic myeloid leukaemia BCR-ABL1 positive, under the 2017 WHO classification",{"count":463,"type":20},"This is a multinational, multicenter, prospective and retrospective, observational, cohort study of patients with myeloproliferative neoplasm.",[175,122,26,484,485,177,229,230],"Post-polycythemia Vera Myelofibrosis","Post-essential Thrombocythemia Myelofibrosis",[487,488,489,490],"Myeloproliferative neoplasm","Epidemiology","Outcome","Prognostic factors","2023-05-21",{"date":493,"type":36},"2023-05-31",{"date":495,"type":20},"2023-05",{"date":497,"type":20},"2026-12",{"name":499,"class":80},"The University of Hong Kong"]